Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Matridx Bio Closes $32 Million for Pathogen Metagenomics Analyzers

publication date: Jan 25, 2021

Matridx Biotech of Hangzhou closed a $32 million Series B round to support its pathogen metagenomics devices, which are based on AI and CRISPR-Cas technologies. So far, the company has developed two products: a SARS-CoV-2 nucleic acid detection kit, and a metagenomic next-gen sequencing (mNGS) device that diagnoses over 16,000 DNA pathogens (bacteria, DNA viruses, fungi, parasites) and 200 RNA viruses (HIV, coronaviruses, Dengue viruses etc.). Matridx says its technology offers faster speed, better accuracy and wider detection coverage than the competition. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here